Premarket evidence and postmarketing requirements for real-time oncology review indication approvals Research Letter
| Authors: | Mooghali, M.; Mohammad, A.; Wallach, J. D.; Mitchell, A. P.; Ross, J. S.; Ramachandran, R. |
| Title: | Premarket evidence and postmarketing requirements for real-time oncology review indication approvals |
| Keywords: | controlled study; placebo; antineoplastic agents; drug approval; united states; united states food and drug administration; disease marker; antineoplastic agent; neoplasm; neoplasms; food and drug administration; oncology; drug surveillance program; medical oncology; cross-sectional study; clinical effectiveness; postmarketing surveillance; drug indication; clinical outcome; procedures; humans; human; article; product surveillance, postmarketing; malignant neoplasm; real time oncology review |
| Journal Title: | JAMA Network Open |
| Volume: | 7 |
| Issue: | 5 |
| ISSN: | 2574-3805 |
| Publisher: | American Medical Association |
| Date Published: | 2024-05-01 |
| Start Page: | e249233 |
| Language: | English |
| DOI: | 10.1001/jamanetworkopen.2024.9233 |
| PUBMED: | 38691363 |
| PROVIDER: | scopus |
| PMCID: | PMC11063797 |
| DOI/URL: | |
| Notes: | Article -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed -- Source: Scopus |
